…for patients receiving tolebrutinib 60 mg for >8 weeks; 68.5% were relapse-free. EDSS scores remained stable to week 144. The incidence of elevated liver enzymes was 5%. MRI outcomes were reported separately (Reich et al. ECTRIMS/ACTRIMS 2023;P684). For the group on continuous tolebrutinib 60 mg, the mean number of new Gd+ lesions from the previous scan was 0.48 at week 144; 79.3% had no new Gd+ lesions. Mean T2 volume was reduced from 12.74 cm3…

…old, respectively, above normal values (Z score 0) were associated with a 2- to 3-fold higher risk of progression in PPMS patients. The highest risk of disability progression was seen in PPMS patients with high GFAP and low NfL levels, which may have indicated a neurodegenerative subgroup with nonactive disease. Impact of obesity on MS Recent studies have suggested that obese individuals diagnosed with MS experience more rapid disability progressi…